NASDAQ:CYCN - Cyclerion Therapeutics Stock Price, Forecast & News

Cyclerion Therapeutics trades on the NASDAQ under the ticker symbol "CYCN."

Cyclerion Therapeutics Inc (NASDAQ:CYCN) posted its earnings results on Tuesday, November, 12th. The company reported ($1.00) earnings per share (EPS) for the quarter. The company had revenue of $1.40 million for the quarter. View Cyclerion Therapeutics' Earnings History.

Cyclerion Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, February 11th 2020. View Earnings Estimates for Cyclerion Therapeutics.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cyclerion Therapeutics in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Cyclerion Therapeutics.

Press coverage about CYCN stock has trended positive this week, according to InfoTrie Sentiment. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cyclerion Therapeutics earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for Cyclerion Therapeutics.

Cyclerion Therapeutics saw a increase in short interest in December. As of December 31st, there was short interest totalling 776,000 shares, an increase of 6.3% from the December 15th total of 730,200 shares. Based on an average trading volume of 844,100 shares, the short-interest ratio is currently 0.9 days. Approximately 3.0% of the company's shares are short sold. View Cyclerion Therapeutics' Current Options Chain.

Some companies that are related to Cyclerion Therapeutics include Recro Pharma (REPH), Avid Bioservices (CDMO), Mersana Therapeutics (MRSN), Merus (MRUS), OptiNose (OPTN), Minerva Neurosciences (NERV), Stemline Therapeutics (STML), CytomX Therapeutics (CTMX), Puma Biotechnology (PBYI), Galera Therapeutics (GRTX), INDIVIOR PLC/S (INVVY), OrganiGram (OGI), Albireo Pharma (ALBO), Kalvista Pharmaceuticals (KALV) and MannKind (MNKD).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cyclerion Therapeutics investors own include Lexicon Pharmaceuticals (LXRX), Solid Biosciences (SLDB), ACADIA Pharmaceuticals (ACAD), Agenus (AGEN), Agile Therapeutics (AGRX), Arrowhead Pharmaceuticals (ARWR), Antares Pharma (ATRS), Axsome Therapeutics (AXSM), Clovis Oncology (CLVS) and Corbus Pharmaceuticals (CRBP).

Shares of CYCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CYCN stock can currently be purchased for approximately $3.21.

Cyclerion Therapeutics has a market capitalization of $88.18 million. View Additional Information About Cyclerion Therapeutics.

The official website for Cyclerion Therapeutics is http://www.cyclerion.com/.

Cyclerion Therapeutics' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The company can be reached via phone at 857-327-8778 or via email at [email protected]